Cryoport 3Q 2026: Revenue $50.22M, EPS ($0.25) — 10-Q Summary
Cryoport’s third-quarter revenue rose 13.5% year over year, while its net loss widened. Growth in Life Sciences Services and Products revenue was partly offset by higher costs; increased unrealized losses on short-term investments also weighed on results.Financial Highlights¹ Reported as “Total rev…
Story updates
10:33:20 PM UTC
SquawkNews
Cryoport, Inc. reported third-quarter 2026 revenue of $50.2 million, representing a 14% year-over-year increase. The company highlighted a 20% year-over-year growth in commercial cell and gene therapy revenue and noted that it is supporting 788 global clinical trials and 23 commercially approved therapies. Following these results, the company raised its full-year 2026 revenue guidance to a range of $197 million to $199 million. Management attributed the performance to the continued adoption of its integrated supply chain solutions and the increasing number of patients receiving cell and gene therapy treatments.